spacer
home > events calendar > more about event
PHARMACEUTICAL INDUSTRY EVENTS CALENDAR

SMi presents the 13th Conference on ADMET

9-10 July 2018
Holiday Inn Kensington Forum, London, UK

SMi is delighted to announce the 13th annual ADMET conference returning to London on the 9th - 10th July 2018, featuring.

Developments in ADMET and novel technologies determine the properties of a drug candidate in the preclinical stage of drug discovery. Poor ADMET properties are the principal cause for a candidate to fail at any stage of drug development. ADME-Toxicology and Pharmacokinetic studies are the key strategic check-points for pharmaceutical companies to reduce drug discovery cost and minimise production times.

The growing use of ADMET technologies is driving the market growth, which is estimated to reach $14,319.9 Million by 2022, with a CAGR of 10.6% from 2016 to 2022*. The main objective of early prediction of ADME properties of a compound is to increase the success rate of it reaching the development stage.

*Source: http://bit.ly/2hMJcgU

Who should attend?

  • DMPK Professionals 
  • Pharmacologists 
  • Computational Scientists 
  • Medicinal Chemists 
  • Statisticians 
  • Principle scientist 
  • Drug Metabolism Experts 
  • ADME Toxicologists 
  • Research fellows 
  • PK/PD modelling 
  • Toxicologist 
  • Anatomists 

Join our expert speaker panels at the ADMET conference to ensure you do not miss out on the latest developments!

Presenting new technologies, specific case studies and PK modelling strategies in the areas of DMPK, PBPK, PKPD, in vitro/ex vivo/in vivo/in silico, biologics, transporters, hazard and safety assessments, ADMET modelling, and many more.

This event is CPD accredited.

#SMiADMET

 
Print this page
Send to a friend
   
Banner of Bio Trinity_Events_Page on Samedan
spacer
Industry Events

Highly Potent Active Pharmaceutical Ingredients (HPAPI)

13-14 May 2019, Copthorne Tara Hotel, London, UK

SMi is delighted to announce its 3rd Annual Highly Potent Active Pharmaceutical Ingredients conference coming to London on the 13th-14th May 2019. The HPAPI global market has developed rapidly in the past year and is continuing to expand into the future, with over a quarter of drugs in development worldwide being classified as highly potent. As a result, there is a growing demand for both pharmaceutical and contracted manufacturers to adapt to the evolving HPAPI landscape.
More info >>

White Papers

Recommendations for Implementing Assessment Criteria Guidelines in Lymphoma and Chronic Lymphocytic Leukemia Clinical Trials

Perceptive Informatics

Standardized assessment criteria are becoming increasingly important in obtaining valid outcomes in oncology clinical trials. While standardized criteria encourage a more uniform approach to assessing clinical trial data, they are often subject to the interpretation of the user. These differences in interpretation, while seemingly minor, can have a major impact on assessments. The most commonly used standardized criteria for lymphoma have been no exception. Differences such as minimum new lesion size, lymph node normalization size requirements, inclusion of extranodal lesions and assessment of organomegaly can have a profound effect on overall response. Additionally, heightened scrutiny of the assessment criteria used in a given protocol can lead to questions about a drug’s efficacy if not applied correctly according to regulators’ interpretation.
More info >>


News and Press Releases

Realising the potential of single-use technology – As published in Manufacturing Chemist

In this article Zenith Technologies’ Global Director of Managed Services David Staunton and Scott Ripley, Global Marketing Director at GE Healthcare, discuss the benefits and patient impact of single-use technology with Manufacturing Chemist.
More info >>

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement